Recent advances in antigen targeting to antigen-presenting cells in veterinary medicine

Abstract

Advances in antigen targeting in veterinary medicine have gained traction over the years as an alternative approach for diseases that remain a challenge for traditional vaccines. In addition to the nature of the immunogen, antigen-targeting success relies heavily on the chosen receptor for its direct influence on the elicited response that will ensue after antigen uptake. Different approaches using antibodies, natural or synthetic ligands, fused proteins, and DNA vaccines have been explored in various veterinary species, with pigs, cattle, sheep, and poultry as the most frequent models. Antigen-presenting cells can be targeted using a generic approach, such as broadly expressed receptors such as MHC-II, CD80/86, CD40, CD83, etc., or focused on specific cell populations such as dendritic cells or macrophages (Langerin, DC-SIGN, XCR1, DC peptides, sialoadhesin, mannose receptors, etc.) with contrasting results. Interestingly, DC peptides show high specificity to DCs, boosting activation, stimulating cellular and humoral responses, and a higher rate of clinical protection. Likewise, MHC-II targeting shows consistent results in enhancing both immune responses; an example of this strategy of targeting is the approved vaccine against the bovine viral diarrhea virus in South America. This significant milestone opens the door to continuing efforts toward antigen-targeting vaccines to benefit animal health. This review discusses the recent advances in antigen targeting to antigen-presenting cells in veterinary medicine, with a special interest in pigs, sheep, cattle, poultry, and dogs.

The dynamic shifts of IL-10-producing Th17 and IL-17-producing Treg in health and disease: a crosstalk between ancient "Yin-Yang" theory and modern immunology

“…These cells play a pivotal role in capturing and processing antigens, subsequently presenting them to T cells to initiate specific immune responses [143,144]. Notably, among APCs, DCs exhibit the most robust antigen-presenting capabilities [145]. Extensive research has elucidated the regulatory influence of DCs on the differentiation of Treg and Th17 [146][147][148][149][150].…”

Therapeutic Applications of Nanomedicine: Recent Developments and Future Perspectives

“…Over the past 20 years, antigen targeting tactics have been extensively investigated as preventive and therapeutic measures for infectious illnesses, autoimmunity, and cancer. These strategies have been created to improve vaccine efficiency through this mechanism of antigen capture [87]. Antigen presentation on the surface of NPs resembles the natural manner in which viruses present antigen and by managing and delaying the antigen's release, NPs can regulate the immune system's exposure to it.…”

Characterization of Canine Peyer’s Patches by Multidimensional Analysis: Insights from Immunofluorescence, Flow Cytometry, and Single-Cell RNA Sequencing

“…“Microfold” or M cells, specialized cells with a key role in mucosal response induction in the GALT and the generation of IgA responses ( 14 ), have not been thoroughly characterized in dogs. Given their role in the GALT, various strategies have been developed for targeting these cells for mucosal vaccination, in both humans ( 15 ) and veterinary medicine ( 16 ). Vaccination with a molecule targeting M cells in mice, but not guinea pigs, has been shown to improve IgA and cellular responses in mice ( 16 ).…”

“…Given their role in the GALT, various strategies have been developed for targeting these cells for mucosal vaccination, in both humans ( 15 ) and veterinary medicine ( 16 ). Vaccination with a molecule targeting M cells in mice, but not guinea pigs, has been shown to improve IgA and cellular responses in mice ( 16 ). However, the presence and frequency of these cells in dogs will need to be evaluated to determine the feasibility of this strategy in this species.…”